Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SL Science HoldingSLBT +24.39%12 EV-to-OCF is -965.37 as of Aug. 04, 2026. GuruFocus rates SLBT with a GF Score™ of 12/100. The stock has 3 warning signs investors should review. Among 1,410 Biotechnology companies, SL Science Holding ranks better than 99.29% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, SL Science Holding's Enterprise Value is $1,843.85 Mil.
SL Science Holding's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $-1.91 Mil. Therefore, SL Science Holding's EV-to-OCF for today is -965.37.
The historical rank and industry rank for SL Science Holding's EV-to-OCF or its related term are showing as below:
SLBT'
s EV-to-OCF Range Over the Past 10 Years
Min: -1758.07 Med: -1261.9 Max: -765.73
Current: -965.37
During the past 3 years, the highest EV-to-OCF of SL Science Holding was -765.73. The lowest was -1758.07. And the median was -1261.90.
SLBT's EV-to-OCF is ranked better than 99.29% of 1410
companies
in the Biotechnology industry
Industry Median: -3.23
vs SLBT: -965.37
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
SL Science Holding's PE Ratio (TTM) for today is calculated as:
SL Science Holding's share price for today is $3.29.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. SL Science Holding's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.007.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
SL Science Holding EV-to-OCF Related Terms
SL Science Holding EV-to-OCF Historical Data
* Premium members only.
The historical data trend for SL Science Holding's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SL Science Holding EV-to-OCF Chart
SL Science Holding Annual Data
Trend
Dec23
Dec24
Dec25
EV-to-OCF
0.00
0.00
0.00
SL Science Holding Semi-Annual Data
Dec23
Jun24
Dec24
Jun25
Dec25
EV-to-OCF
0.00
0.00
0.00
0.00
0.00
SLBT vs DMRA, BCAX, TYRA: EV-to-OCF Comparison
For the Biotechnology subindustry, SL Science Holding's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SL Science Holding EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SL Science Holding's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where SL Science Holding's EV-to-OCF falls into.
SL Science Holding's current Enterprise Value is $1,843.85 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. SL Science Holding's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $-1.91 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SL Science Holding (SLBT) has a EV-to-OCF of -965.37 as of Aug. 04, 2026. According to the industry distribution chart, SL Science Holding ranks #10 out of 1410 companies in the Biotechnology industry, placing it in the top 0.7%.
Is SL Science Holding's EV-to-OCF too high?
SL Science Holding's current EV-to-OCF is -965.37. Based on the distribution chart, SL Science Holding ranks #10 out of 1410 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, SL Science Holding has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does SL Science Holding's EV-to-OCF compare to DMRA and BCAX?
According to the Biotechnology industry distribution chart, SL Science Holding ranks #10 out of 1410 companies for EV-to-OCF. This places SL Science Holding in the top 1% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. SL Science Holding's current EV-to-OCF is -965.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SL Science Holding stock overvalued right now?
SL Science Holding (SLBT) has a current EV-to-OCF of -965.37. The current EV-to-OCF is -965.37. SL Science Holding's overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For SL Science Holding (SLBT), the current EV-to-OCF is -965.37 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.
12GF Score
Get the complete analysis for SLBT
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLBT has been successfully added to your 
